Paul McNally


Paul McNally

Associate Professor of Paediatrics

Paul graduated from the UCD School of Medicine in 1998. He completed his paediatric medical training in Ireland, and subsequently completed a 2-year MD in Cystic Fibrosis (CF) lung disease in the Royal College of Surgeons in Ireland. Paul undertook pulmonology fellowship training in the Children’s Hospital of Philadelphia from 2007 to 2009. He was appointed as a consultant in Paediatric Respiratory Medicine at Our Lady’s Children’s Hospital (OLCHC) in 2009. In August 2015, Paul was appointed as Associate Professor of Paediatrics at RCSI. Paul is director of the CF centre in OLCHC and leads the CF research group at NCRC. Paul is clinical lead for Paediatric Respiratory Medicine in the Dublin Paediatric Hospitals. He is a member of the medical and scientific council of CF Ireland and the Scientific Advisory Committee of the CF Registry of Ireland. Paul is a member of the working group of the National Clinical Programme for Cystic Fibrosis and is a member of the advisory board for the National Clinical Programme for Paediatrics. Paul’s main research interest is early CF lung disease, in particular around the question of why some children have more severe lung disease, and how we can detect these children earlier and modify their treatment.

Paul McNally

Associate Professor of Paediatrics

Jenny Lennon
Position: National CF research Co-ordinator
lennonje@tcd.ie

Role:
Jenny has developed an active CF clinical trials site in OLCHC and now co-ordinates all CF clinical research and clinical trials in OLCHC and throughout Ireland via the CF: INK clinical research network.

Dr Rebecca Reilly
Position: Clinical Research Coordinator, Children’s Clinical Research Unit
rebecca.reilly@ncrc.ie

Role:
Rebecca is co-ordinator for clinical research in OLCHC and throughout the SHIELD CF network. She manages the SHIELD CF biobank and databank. She also works on a number of interventional and non interventional clinical trials.

Aine Fleming
Position: Clinical Research Coordinator
aine.fleming@ncrc.ie

Role:
Aine is the primary coordinator for a non-interventional clinical trial ongoing at multiple CF centres in Ireland. She is also works on a number of CF research projects.

Rebecca McLoughlin
Position: Research Respiratory Physiologist
rebecca.mcloughlin@ncrc.ie

Role:
Rebecca is coordinating a research study looking at a new lung function measurement device which the CF centre in Crumlin have recently acquired, called the Exhalyzer D a Multiple Breath Washout (MBW) test. Rebecca aims to validate the test in a population of healthy Irish children and in children with cystic fibrosis.

The Study of Host Immunity and Early Lung Disease in CF (SHIELD CF)

SHIELD CF is an ambitious long term translational research programme based in NCRC and running in the CF centres in OLCHC, Tallaght and Limerick. SHIELD CF is based around our annual assessment service, which includes a range of blood tests, x-rays, lung function tests and a bronchoscopy in children who cannot produce sputum specimens. Children are followed up until adulthood. All samples that are taken are catalogued and stored in a specialised biobank for current and future use. In parallel to our clinical sample collection, we are collecting a wide array of clinical information about our patients including complications of the disease and access to medical care. The design of the program allows for a significant degree of collaboration with national and international colleagues in an effort to gain a greater understanding of lung disease in children with CF.

The airway microbiome in children with CF (AIM CF)

In recent years we have come to understand that a vast array of bacteria lives in our airways – even in healthy people. It has become clear that the interaction between the healthy and harmful bacteria in the lungs is complex. We are conducting a long term and very wide-ranging study in children with CF looking at how these bacteria vary over time and whether they are related to lung inflammation, changes in antibiotic use and lung function at school age.

Inflammatory and Microbiological Implications of Pooling of Bronchoalveolar Lavage samples in Preschool Children with Cystic Fibrosis (the POOL study)

Bronchoalveolar lavage fluid is collected when salt water is instilled temporarily in the lungs during a bronchoscopy procedure. It collects the proteins and bacteria from the lower airways that otherwise could not be collected. This is potentially a very useful test for clinical trials of new medications in children with CF, but there are several different approaches internationally to the way the test is performed. This multicentre study seeks to determine if different ways of handling and processing the fluid impact on its utility as a marker of lung pathology.

CF Urinary biomarker study (CUBS)

Lots of substances that are produced in the body are excreted in the urine. This has been shown to be true of markers of lung damage in people with lung diseases. This is of significant interest to doctors looking after children with CF as the collection of urine is a painless and harmless procedure, urine is always accessible, and it is an easy fluid to work with. This study is looking to collect information about what substances are in the urine, how they naturally vary over time and whether we can see any patterns in these substances relating to lung infection and inflammation in children with CF. We are working with a company called Mologic in the UK who have experience in this area and are currently working on a similar study to this in adults with CF.

Protease activity: Lung Measurement in Children with Cystic Fibrosis (PALM)

This is a longitudinal study looking at a type of enzyme called a protease. Different types of proteases such as neutrophil elastase, are risk factors for lung damage in children with CF. Presently not a lot is known about the role of other proteases in the preschool CF lung. The study is designed to establish the degree and pattern of protease and anti-protease activity (PAPA) in the lungs of preschool children with CF, and to determine if specific proteases or anti-proteases are associated with either pulmonary infection or clinical disease parameters. The study also proposes to determine whether markers of PAPA can be detected in urine.



The list of publications below is automatically derived from MEDLINE/PubMed. As a result, there may be incorrect or missing publications.

Ringholz FC, Higgins G, Hatton A, Sassi A, Moukachar A, Fustero-Torre C, Hollenhorst M, Sermet-Gaudelus I, Harvey BJ, McNally P, Urbach V, 2017 Dec 7, Resolvin D1 regulates epithelial ion transport and inflammation in cystic fibrosis airways. J Cyst Fibros, DOI: 10.1016/j.jcf.2017.11.017
McNally P, O'Rourke J, Fantino E, Chacko A, Pabary R, Turnbull A, Grant T, O'Sullivan N, Wainwright C, Linnane B, Davies JC, Sly PD, 2018 May, Pooling of bronchoalveolar lavage in children with cystic fibrosis does not adversely affect the microbiological yield or sensitivity in detecting pulmonary inflammation. J Cyst Fibros, DOI: 10.1016/j.jcf.2017.10.016
Higgins G, Fustero Torre C, Tyrrell J, McNally P, Harvey BJ, Urbach V, 2016 Jun 1, Lipoxin A4 prevents tight junction disruption and delays the colonization of cystic fibrosis bronchial epithelial cells by Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol, DOI: 10.1152/ajplung.00368.2015
Mirković B, Murray MA, Lavelle GM, Molloy K, Azim AA, Gunaratnam C, Healy F, Slattery D, McNally P, Hatch J, Wolfgang M, Tunney MM, Muhlebach MS, Devery R, Greene CM, McElvaney NG, 2015 Dec 1, The Role of Short-Chain Fatty Acids, Produced by Anaerobic Bacteria, in the Cystic Fibrosis Airway. Am J Respir Crit Care Med, DOI: 10.1164/rccm.201505-0943OC
McGovern E, McNally P, O'Sullivan M, Phelan E, Sumner K, Best DH, McMahon CJ, 2016 Apr, Infantile pulmonary capillary haemangiomatosis: a lethal form of pulmonary hypertension. Cardiol Young, DOI: 10.1017/S1047951115001006
Oglesby IK, Vencken SF, Agrawal R, Gaughan K, Molloy K, Higgins G, McNally P, McElvaney NG, Mall MA, Greene CM, 2015 Nov, miR-17 overexpression in cystic fibrosis airway epithelial cells decreases interleukin-8 production. Eur Respir J, DOI: 10.1183/09031936.00163414
Linnane B, Clarke D, Murray P, O'Sullivan N, Dunne C, McNally P, 2015 Oct, The benefit of taking a control sample when performing bronchoalveolar lavage. Thorax, DOI: 10.1136/thoraxjnl-2015-207319
Gaffney C, McNally P, 2015 Jun, Successful use of acetazolamide for central apnea in a child with Pitt-Hopkins syndrome. Am J Med Genet A, DOI: 10.1002/ajmg.a.37034
Higgins G, Ringholz F, Buchanan P, McNally P, Urbach V, 2015, Physiological impact of abnormal lipoxin A₄ production on cystic fibrosis airway epithelium and therapeutic potential. Biomed Res Int, DOI: 10.1155/2015/781087
Glasgow AM, Small DM, Scott A, McLean DT, Camper N, Hamid U, Hegarty S, Parekh D, O'Kane C, Lundy FT, McNally P, Elborn JS, McAuley DF, Weldon S, Taggart CC, 2015 May, A role for whey acidic protein four-disulfide-core 12 (WFDC12) in the regulation of the inflammatory response in the lung. Thorax, DOI: 10.1136/thoraxjnl-2014-206488
Renwick J, McNally P, John B, DeSantis T, Linnane B, Murphy P, SHIELD CF., 2014, The microbial community of the cystic fibrosis airway is disrupted in early life. PLoS One, DOI: 10.1371/journal.pone.0109798
Linnane B, Vaish S, Clarke D, O'Sullivan N, McNally P, 2015 Apr, The findings of a clinical surveillance bronchoalveolar lavage programme in pre-school patients with cystic fibrosis. Pediatr Pulmonol, DOI: 10.1002/ppul.23118
Small DM, Zani ML, Quinn DJ, Dallet-Choisy S, Glasgow AM, O'Kane C, McAuley DF, McNally P, Weldon S, Moreau T, Taggart CC, 2015 Jan, A functional variant of elafin with improved anti-inflammatory activity for pulmonary inflammation. Mol Ther, DOI: 10.1038/mt.2014.162
Al-Alawi M, Buchanan P, Verriere V, Higgins G, McCabe O, Costello RW, McNally P, Urbach V, Harvey BJ, 2014 Aug 1, Physiological levels of lipoxin A4 inhibit ENaC and restore airway surface liquid height in cystic fibrosis bronchial epithelium. Physiol Rep, DOI: 10.14814/phy2.12093
Weldon S, McNally P, McAuley DF, Oglesby IK, Wohlford-Lenane CL, Bartlett JA, Scott CJ, McElvaney NG, Greene CM, McCray PB Jr, Taggart CC, 2014 Jul 15, miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S production. Am J Respir Crit Care Med, DOI: 10.1164/rccm.201311-1986OC
Ringholz FC, Buchanan PJ, Clarke DT, Millar RG, McDermott M, Linnane B, Harvey BJ, McNally P, Urbach V, 2014 Aug, Reduced 15-lipoxygenase 2 and lipoxin A4/leukotriene B4 ratio in children with cystic fibrosis. Eur Respir J, DOI: 10.1183/09031936.00106013
Higgins G, Buchanan P, Perriere M, Al-Alawi M, Costello RW, Verriere V, McNally P, Harvey BJ, Urbach V, 2014 Aug, Activation of P2RY11 and ATP release by lipoxin A4 restores the airway surface liquid layer and epithelial repair in cystic fibrosis. Am J Respir Cell Mol Biol, DOI: 10.1165/rcmb.2012-0424OC
O'Donovan C, Greally P, Canny G, McNally P, Hussey J, 2014 May, Active video games as an exercise tool for children with cystic fibrosis. J Cyst Fibros, DOI: 10.1016/j.jcf.2013.10.008
Ringholz F, Devins M, McNally P, 2014 Mar, Managing end stage lung disease in children. Paediatr Respir Rev, DOI: 10.1016/j.prrv.2013.07.002
Buchanan PJ, McNally P, Harvey BJ, Urbach V, 2013 Jul 15, Lipoxin A₄-mediated KATP potassium channel activation results in cystic fibrosis airway epithelial repair. Am J Physiol Lung Cell Mol Physiol, DOI: 10.1152/ajplung.00058.2013
Palfreeman A, Nyatsanza F, Farn H, McKinnon G, Schober P, McNally P, 2013 Jun, HIV testing for acute medical admissions: evaluation of a pilot study in Leicester, England. Sex Transm Infect, DOI: 10.1136/sextrans-2011-050401
Verrière V, Higgins G, Al-Alawi M, Costello RW, McNally P, Chiron R, Harvey BJ, Urbach V, 2012, Lipoxin A4 stimulates calcium-activated chloride currents and increases airway surface liquid height in normal and cystic fibrosis airway epithelia. PLoS One, DOI: 10.1371/journal.pone.0037746
Linnane B, McNally P, 2011 Oct 26, Bronchoalveolar lavage-directed therapy in children with cystic fibrosis and Pseudomonas aeruginosa infection. JAMA, DOI: 10.1001/jama.2011.1518
Vega-Carrascal I, Reeves EP, Niki T, Arikawa T, McNally P, O'Neill SJ, Hirashima M, McElvaney NG, 2011 Mar 1, Dysregulation of TIM-3-galectin-9 pathway in the cystic fibrosis airways. J Immunol, DOI: 10.4049/jimmunol.1003187
Weldon S, McNally P, McElvaney NG, Elborn JS, McAuley DF, Wartelle J, Belaaouaj A, Levine RL, Taggart CC, 2009 Dec 15, Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation. J Immunol, DOI: 10.4049/jimmunol.0901716
Nino G, McNally P, Miske LJ, Hickey E, Panitch HB, 2009 Nov, Use of intrapulmonary percussive ventilation (IPV) in the management of pulmonary complications of an infant with osteogenesis imperfecta. Pediatr Pulmonol, DOI: 10.1002/ppul.21112
Bergsson G, Reeves EP, McNally P, Chotirmall SH, Greene CM, Greally P, Murphy P, O'Neill SJ, McElvaney NG, 2009 Jul 1, LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline. J Immunol, DOI: 10.4049/jimmunol.0803959
Guyot N, Butler MW, McNally P, Weldon S, Greene CM, Levine RL, O'Neill SJ, Taggart CC, McElvaney NG, 2008 Nov 21, Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis. J Biol Chem, DOI: 10.1074/jbc.M803707200
McNally PG, Dean JD, Morris AD, Wilkinson PD, Compion G, Heller SR, 2007 May, Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. Diabetes Care, DOI: 10.2337/dc06-1328
McNally P, McNicholas F, Oslizlok P, 2007 Feb, The QT interval and psychotropic medications in children: recommendations for clinicians. Eur Child Adolesc Psychiatry, DOI: 10.1007/s00787-006-0573-0
Kong MF, Jogia R, Jackson S, Quinn M, McNally P, Davies M, 2005 Nov 12, Malignant melanoma presenting as a foot ulcer. Lancet, DOI: 10.1016/S0140-6736(05)67701-X

Funding Agency:National Children’s Research Centre
Project Title:The Study of Host Immunity and Early Lung Disease in Children with CF (SHIELD CF)
Start Date/End Date:2009 – present
Total Awarded:€350k
Role:PI
Funding Agency:National Children’s Research Centre / National Children’s Hospital foundation
Project Title:Polymicrobial Communities in The Lower Airways of Children with Cystic Fibrosis: Development, Diversity and Consequences on Lung InflammationStart Date/End
Start Date/End Date:2010 – present
Total Awarded:€280k
Role:Co-PI
Funding Agency:National Children’s Research Centre
Project Title:Physiological Impact of Lipoxins on the Function of Lung Epithelium in Children with Cystic Fibrosis
Start Date/End Date:2010 – 2012
Total Awarded:€385k
Role:Co-PI
Funding Agency:Health Research Board
Project Title:Lipoxin synthesis in children with cystic fibrosis and pro-resolution actions in airway epithelium
Start Date/End Date:2011 – 2013
Total Awarded:€350k
Role:Co-PI
Funding Agency:Health Research BoardProject
Project Title:The role of mucus and mucins in mediating P aeruginosa colonisation in the CF lung.
Start Date/End Date:2011-2013
Total Awarded: €172k
Role:Co-Applicant.
Funding Agency:National Children’s Research Centre
Project Title:MicroRNA modulation of aberrant interleukin-8 expression in cystic fibrosis bronchial epithelial cells.
Start Date/End Date:2013-2016
Total Awarded:€195k
Role:Co-Applicant
Name:Dr Barry Linnane
Position:Consultant in Paediatric Respiratory Medicine
Email:Barry.Linnane@hse.ie
Role:Dr Linnane is paediatric CF centre director in University Hospital Limerick and co-founder of SHIELD CF. He is an active clinical researcher and local principle investigator on several international clinical trials.
Name:Dr Des Cox
Position:Consultant in Paediatric Respiratory Medicine
Email:des.cox@olchc.ie
Role:Dr Cox is head of the Department of Respiratory Medicine in OLCHC, and an active lead researcher in the CF Research group. He is local principal investigator on several international clinical trials.
Name:Dr Judith Coppinger
Position: Senior Lecturer, RCSI
Email:Judith.coppinger@ncrc.ie
Role:Judith is an accomplished scientist who has worked in leading institutions in Ireland and North America, and published extensively in the areas of CF and cancer. Judith heads up the basic science research core in NCRC.
Name:Dr Peter Greally
Position:Consultant in Paediatric Respiratory Medicine
Email:peter.greally@amnch.ie
Role:Dr Greally is CF centre director in Tallaght Hospital. He is an active clinical researcher and local principle investigator on several international clinical trials.
Name:Dr David Rea
Position:Consultant Paediatric Radiologist
Email:david.rea@olchc.ie
Role:Dr Rea is a consultant paediatric radiologist in OLCHC. He is lead radiologist for the SHIELD CF network. Dr Rea leads the imaging analysis aspects of SHIELD CF. OLCHC is part of the SciFi network – an international imaging network for children with CF
Name:Dr Michael McDermott
Position:Consultant Paediatric Pathologist
Email:Michael.mcdermott@olchc.ie
Role:Dr McDermott is a consultant paediatric pathologist in OLCHC. He is lead pathologist for the SHIELD CF network, and leads the optimization of techniques for cell imaging and analysis for SHIELD CF.
Name:Professor Ivo Leuschner
DepartmentPathology, Division of Paediatric Pathology, Institution: Christian-Albrechts
Institution:University Kiel,
Country:Germany
Name:Dr. Christian Vokuhl
DepartmentPathology Institution
Institution:Christian-Albrechts University, Kiel
Country:Germany
Name:Professor Manfred Gessler
DepartmentTheodor-Boveri-Institute/Biocenter,
Institution:Developmental Biochemistry, and Comprehensive Cancer Center Mainfranken, Wuerzburg University, 97074 Wuerzburg.
Country:Germany
Name:Professor Norbert Graf
DepartmentPaediatric Oncology and Hematology
Institution:Saarland University Hospital, Homburg
Country:Germany
Name:Professor Adrian Bracken
DepartmentGenetics
Institution:Smurfit Institute, Trinity College, Dublin
Country:Ireland
Name:Dr. Gerard Cagney
DepartmentConway Institute
Institution:University College Dublin
Country:Ireland

Current Trials & Studies

Study NameStudy TitleStudy TypeSponsorSponsor Type
SHIELD CFThe Study of Host Immunity and Early Lung Disease in Children with CFNon-Interventional StudyNCRCAcademic - Investigator Led
VX14-661-110A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR MutationClinical TrialVertexIndustry Sponsored
VOICE: VX14-CFR-107Observational Registry of Cystic Fibrosis Patients in EuropeNon-interventional studyVertexIndustry Sponsored
CUBS (CF Urinary biomarker study)CF Urinary biomarker studyNon-interventional studyNCRCAcademic - Investigator Led
PALM StudyPALM study (Protease activity: Lung measurement) – a longitudinal study in children with CF to establish spectrum and influence of protease antiprotease activity in CF Starting in JulyNon-Interventional StudyNCRCAcademic - Investigator Led
VX15-770-124A Phase 3, 2-Part, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have a CFTR Gating MutationClinical TrialVertexIndustry Sponsored
VX15-770-126A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have a CFTR Gating Mutation.Clinical TrialVertexIndustry Sponsored

Previous Trials & Studies

Study NameStudy TitleStudy TypeSponsorSponsor Type
VX15-371-101A Phase 2a, Randomized, Double-blind, Placebo-controlled, Incomplete Block, Crossover Study to Evaluate the Safety and Efficacy of VX-371 in Subjects Aged 12 Years or Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation, and Being Treated With OrkambiClinical TrialVertexIndustry Sponsored
VX14-661-106A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With IvacaftorClinical TrialVertexIndustry Sponsored
VX14-661-109A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR MutationClinical TrialVertexIndustry Sponsored
VX12-809-103A Phase 3, Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination with Ivacaftor in Subjects Aged 12 years and older with Cystic Fibrosis, Homozygous for the F508del CFTR Mutation (TRAFFIC)Clinical TrialVertexIndustry Sponsored
VX12-809-105A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR MutationClinical TrialVertexIndustry Sponsored
MPEX-209A Phase 3, Open-label, Randomised Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation solution (Aeroquin) versus Tobramycin Inhalation Solution in stable Cystic Fibrosis patientsClinical TrialMpex Pharmaceuticals Inc.Industry Sponsored
VX08-770-103A Phase 3, 2-Part, Randomised, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Pharmacokinetics, Efficacy and Safety of VX-770 in Subjects Aged 6 -11 years with Cystic Fibrosis and G551D mutationClinical TrialVertexIndustry Sponsored
VX08-770-105An Open Label, Rollover Study to Evaluate the Long-Term Safety and Efficacy of VX-770 in Subjects with Cystic FibrosisClinical TrialVertexIndustry Sponsored
TR02-108Randomised, Open Label, Active controlled, multicentre study to assess the efficacy, safety and tolerability of ArikaceTM in Cystic Fibrosis Patients with Chronic Infection due to Pseudomonas AeruginosaClinical TrialInsmed IncIndustry Sponsored
TR02-110Long term safety and tolerability study of open-label liposomal amikacin for inhalation (Arikace) in Cystic Fibrosis patients with chronic infection due to Pseudomonas AeruginosaClinical TrialInsmed IncIndustry Sponsored
PsAer-IgYProspective randomised, placebo controlled, double-blind, multicentre study (Phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention of recurrence of Pseudomonas aeruginosa infection in cystic fibrosis patientsClinical TrialMukoviszidosAcademic - Collaborative Group
Caregiver Burden StudyCaregiver Burden Study in Cystic Fibrosis in the United States, Germany, United Kingdom and IrelandNon-Interventional StudyVertexIndustry Sponsored
The POOL studyInflammatory and Microbiological Implications of Pooling of Bronchoalveolar Lavage samples in Preschool Children with Cystic FibrosisNon-Interventional StudyNCRCAcademic - Investigator Led
Rhinovirus pilot studyThe Role of Human Rhinovirus Infections in Young Children with Cystic Fibrosis - A Pilot StudyNon-Interventional StudyNCRCAcademic - Investigator Led